Tin tức & Cập nhật

New drug applications approved by US FDA as of 16-30 November 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Low-dose interleukin 2 (IL-2) therapy may be used to treat moderate-to-severe bullous pemphigoid (BP), as shown by earlier treatment responses of patients in a recent study.

Interim data from a phase II trial demonstrate the safety and tolerability of the Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine in adolescents. MVA-BN is a live attenuated, non-replicating orthopoxvirus vaccine licensed in the US for smallpox and mpox prevention.

New drug applications approved by US FDA as of 1-15 November 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

In patients with recessive dystrophic epidermolysis bullosa, treatment with pregabalin appears to substantially reduce pain and itch, according to a randomized crossover trial.

In patients with calciphylaxis, diagnostic delay and complications have dropped over time, according to a study. In addition, the number of deaths has decreased in recent years. These findings stress the importance of awareness to speed up diagnosis.

The incidence of dermatofibrosarcoma protuberans (DFSP) is two times higher among Black than White individuals, reports a study.